We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Treatment of Multidrug-resistant or Rifampicin-resistant Tuberculosis With an All-oral 9-month Regimen Containing Linezolid or Ethionamide in South Africa: A Retrospective Cohort Study.
- Authors
Morgan, Hannah; Ndjeka, Norbert; Hasan, Tasnim; Gegia, Medea; Mirzayev, Fuad; Nguyen, Linh N; Schumacher, Samuel; Schlub, Timothy E; Naidoo, Kogieleum; Fox, Greg J
- Abstract
Background In 2019, the South African tuberculosis program replaced ethionamide with linezolid as part of an all-oral 9-month regimen. We evaluated treatment outcomes for patients assigned to regimens including linezolid in 2019 and ethionamide in 2017. Methods This retrospective cohort study included patients treated for multidrug-resistant/rifampicin-resistant tuberculosis throughout South Africa between 1 January and 31 December 2017 and 1 January to 31 December 2019. The cohort treated with a 9-month regimen containing ethionamide for four months, was compared with a cohort treated with a 9-month regimen containing linezolid for 2 months. The regimens were otherwise identical. Inverse probability weighting of propensity scores was used to adjust for potential confounding. A log-binomial regression model was used to estimate adjusted relative risk (aRR) comparing 24-month outcomes between cohorts including treatment success, death, loss to follow up, and treatment failure. Adverse event data were available for the linezolid cohort. Findings In total, 817 patients were included in the cohort receiving ethionamide and 4244 in the cohort receiving linezolid. No evidence for a difference was observed between linezolid and ethionamide regimens for treatment success (aRR = 0.96, 95% confidence interval [CI].91–1.01), death (aRR = 1.01, 95% CI.87–1.17) or treatment failure (aRR = 0.87, 95% CI.44–1.75). Loss to follow-up was more common in the linezolid group, although estimates were imprecise (aRR = 1.22, 95% CI.99–1.50). Conclusions No significant differences in treatment success and survival were observed with substitution of linezolid for ethionamide as a part of an all-oral 9-month regimen. Linezolid is an acceptable alternative to ethionamide in this shorter regimen for treatment of multidrug-resistant/rifampicin-resistant tuberculosis.
- Subjects
SOUTH Africa; RESEARCH funding; LOGISTIC regression analysis; TREATMENT effectiveness; RETROSPECTIVE studies; RELATIVE medical risk; LONGITUDINAL method; PYRIDINE; MEDICAL records; ACQUISITION of data; LINEZOLID; COMPARATIVE studies; CONFIDENCE intervals; RIFAMPIN
- Publication
Clinical Infectious Diseases, 2024, Vol 78, Issue 6, p1698
- ISSN
1058-4838
- Publication type
Article
- DOI
10.1093/cid/ciae145